Dr. Denise Faustmann, the director of immunobiology at Mass General and associate professor of medicine at Harvard Medical School, is repurposing the common tuberculosis vaccine BCG. Faustmann is currently working on treating Type 1 diabetes with the vaccine, and has two upcoming clinical trials possible with help from Cures Within Reach. Additionally, this treatment may also be useful for other autoimmune diseases, such as Multiple Sclerosis and Sjogren’s Syndrome. This discovery is sparking support for repurposing research elsewhere. Christina Waters, the chief executive officer and founder of Rare Science and vice president of Applied Advocacy at Agility Clinical, says in support of repurposing that“if we stop categorizing disease by these names and we start categorizing disease by biological process, then we’re going to be able to start looking at currently approved drugs,” which saves time, money and potentially lives.
Find out more about Dr. Faustmann’s clinical trials here